

*The National Academies of*  
SCIENCES • ENGINEERING • MEDICINE

Board on Health Sciences Policy

*Roundtable on Translating Genomic-Based Research for Health*

*Forum on Drug Discovery, Development, and Translation*

***Deriving Drug Discovery Value from Large-Scale Genetic Bioresources:  
A Workshop***  
March 22, 2016

**The Keck Center of the National Academies, Room 100  
500 Fifth Street, NW  
Washington, DC 20001**

**MEETING OBJECTIVES**

---

- TO ADDRESS HOW PROGRESS CAN BE MADE IN DISCOVERING AND VALIDATING PROMISING TARGETS AND MEDICINES FOR THOSE TARGETS BY USING DATA COLLECTED FROM LARGE-SCALE GENETIC STUDIES
- TO HIGHLIGHT CURRENT GENOMIC-ENABLED DRUG DISCOVERY ACTIVITIES IN INDUSTRY, ACADEMIA, AND GOVERNMENT AND SHARE BEST PRACTICES FOR STUDY DESIGN AND DATA COLLECTION
- TO EXAMINE ENABLING PARTNERSHIPS AND BUSINESS MODELS TO FACILITATE THE USE OF GENETIC DATA FOR DRUG DISCOVERY

**AGENDA**

---

7:45–8:30 A.M.

Breakfast Available

8:30–8:35 A.M.

**Welcoming Remarks**

Geoffrey Ginsburg, *Genomics Roundtable Co-Chair*

Director, Duke Center for Applied Genomics & Precision Medicine;  
Professor of Medicine and of Pathology and Biomedical Engineering,  
Duke University Medical Center

Russ B. Altman, *Drug Forum Co-Chair*

Professor of Bioengineering, Genetics, and Medicine  
Stanford University

8:35–8:45 A.M.

**Charge to workshop speakers and participants**

Nadeem Sarwar, *Workshop Chair*

President, Andover Product Creation Innovation Systems  
Eisai Inc.

## **SESSION I: DESIGNING COHORTS TO MAXIMIZE DISCOVERY CAPABILITIES**

---

**Objectives:** To explore current gaps and opportunities in data collected in large cohort studies and what elements could enable a robust discovery toolbox.

**Moderator: Geoff Ginsburg, *Genomics Roundtable Co-Chair*; Director, Duke Center for Applied Genomics & Precision Medicine**

8:45–9:30 A.M.

Joe Vockley  
Chief Operating Officer and Chief Scientific Officer  
Senior Vice President  
Inova Translational Medicine Institute

Mark Daly  
Co-director  
Program in Medical and Population Genetics  
Broad Institute

Aris Baras  
Vice President, Co-Head Regeneron Genetics Center  
Regeneron Pharmaceuticals

9:30–9:45 A.M.

**Break**

Kári Stefánsson  
Chairman, CEO, and Founder  
deCODE Genetics

Richard Scheller  
Chief Science Officer  
23andMe

10:15–10:45 A.M.

**Discussion with Speakers and Attendees**

## **SESSION II: CURRENT GENOME-ENABLED DISCOVERY ACTIVITIES RELATED TO BIORESOURCES**

---

**Objectives:** To discuss current activities among stakeholder groups and innovative technologies, to identify gaps, and to explore opportunities for cross-sector engagement.

**Moderator: John Carulli, Director, Precision Medicine, Biogen**

10:45–12:00 P.M.

Russ Altman  
Professor of Bioengineering, Genetics, and Medicine  
Stanford University

Lon Cardon  
Senior Vice President of Alternative Discovery and Development  
Head of Target Sciences  
GlaxoSmithKline

Sohini Chowdhury  
Senior Vice President, Research Partnerships  
Michael J. Fox Foundation

Sally John  
Vice President  
Computational Biology and Genomics  
Biogen Idec

Tim Rolph  
Vice-President Program Value Enhancement  
Pfizer

12:00–12:45 P.M.                    **Discussion with Speakers and Attendees**

12:45–1:45 P.M.                    **WORKING LUNCH**

**SESSION III: BUSINESS MODELS THAT SUPPORT BIORESOURCE DISCOVERY COLLABORATION**

---

**Objectives:** To examine potential precompetitive business models and investments that can support discovery efforts and opportunities across stakeholder groups.

**Moderator: Rajesh Ranganathan, Vice President of Science and Regulatory Advocacy, PhRMA**

1:45–2:45 P.M.                    Lynn Matrisian  
Vice President, Scientific & Medical Affairs  
Pancreatic Cancer Action Network

Meg Ehm  
Director, External Strategic Alliances  
Genetics  
GlaxoSmithKline

David Wholley, Accelerating Medicines Partnership and fNIH  
Director, Research Partnerships  
Foundation for the National Institutes of Health

Chas Bountra  
Professor of Translational Medicine  
Head of Structural Genomics Consortium

University of Oxford

2:45–3:30 P.M.                    **Discussion with Speakers and Attendees**

3:30–3:45 P.M.                    **BREAK**

**SESSION IV: WHERE DO WE GO FROM HERE?**

---

**Objectives:** What are the short-term and long-term next steps for achieving effective collaboration among stakeholders? Are there incentives that should be explored? How can we maximize use of large-scale genetic bioresources to effectively translate research to drug discovery?

**Moderator: Nadeem Sarwar, *Workshop Chair*; President, Andover Product Creation Innovation Systems, Eisai Inc.**

3:45–3:55 P.M.                    Dan Tagle (**10 min. presentation**)  
Associate Director for Special Initiatives  
Office of the Director  
National Center for Advancing Translational Sciences  
National Institutes of Health

3:55–4:25 P.M.                    Panel Discussion (**5 min. remarks each**)  
Chas Bountra  
Mark Daly  
Richard Scheller  
Russ Altman  
Lynn Matrisian  
Lon Cardon

4:25–5:10 P.M.                    **Discussion with Speakers and Attendees**

5:10–5:25 P.M.                    **SESSION HIGHLIGHTS (5 min. remarks each)**  
Geoff Ginsburg  
John Carulli  
Rajesh Ranganathan

5:25–5:30 P.M.                    **CONCLUDING REMARKS**

Nadeem Sarwar, *Workshop Chair*  
President, Andover Product Creation Innovation Systems  
Eisai Inc.

5:30 P.M.                            **ADJOURN**